The Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and pharmaceutical research, development and production, proved to be the ideal location.
The SBD is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association’s Annual General Assembly. As always, the event targets entrepreneurs, investors, researchers, analysts, BD&L, political decision makers, industry stakeholders and media.
Event highlights in 2019 will be:
· 700+ attendees from 20+ countries
· Presentation of the Swiss Biotech Report
· Swiss Biotech Success Stories
· Parallel tracks in the afternoon focused on innovative biotech start-ups and medium-sized biotech companies
· Thematically focused panel discussions on e.g. finance, production and licensing
· Pre-scheduled one-to-one partnering meetings for all attendees
· High-traffic exhibition with ongoing catering
Following a long time collaboration between our associations, the Swiss HLG is joining the Italian HLG to co-organize the Summer Conference 2019 in Milan, Italy.
A great program with experts from Italy, Switzerland and the UK will be discussing “Trends in Business Development & Licensing in the Pharmaceutical and Healthcare industry.”
Networking opportunities are planned to facilitate business contacts and discussions during our social events with cocktail, dinner and a walk in the Navigli area in Milan.?
When: 6th – 7th June 2019
Where: Art Hotel Navigli, Via Angelo Fumagalli, 4, 20143 Milan
Both Swiss HLG and PCLF invited speakers from both countries to share with the audience their successes and above all how partnering influenced success.
Once again, attendance was a real success with around 130 delegates from Switzerland, France, Germany and other European countries.
The conference started with an insightful introduction from Patrick Aebischer, President emeritus, Brain Mind Institute at EPFL, on critical components and factors to build a successful innovation ecosystem between universities, research institutes, tech transfer offices, accelerator, and entrepreneurship.
Following the opening keynote, we had a series of inspiring presentations held by Jurgi Camblong (CEO of SOPHiAGENETICS), Mondher Majoubi (CEO of Innate Pharma), Hervé Affagard (CEO MaaT Pharma), Andreas Emmenegger (CFO of Molecular Partners). Beyond great insights on their promising technologies, participants could learn how they embraced partnering as a cornerstone strategy for the development of their company.
The event closed after a great panel moderated by Marc Ceulemans (Head of Strategic Investment from Novartis), with Michele Ollier (Partner atMedixci), Christoph Kausch (Partner at MTIP), Jean-Philippe Tripet (Partner at Aravis) and Marie Petit (Principal at Villiger Valuation) which touched on various topics such as cultural differences when building and financing start-ups between Europe and the US; key success factors for a start-up, and financing challenges in some countries.
Last but not least, for the first time, we interviewed some of our speakers, and we will be pleased to share their insights very soon.
Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)
The Role of Business Development in Changing Global Times
NH Collection Eurobuilding Hotel, Madrid
Thursday 28th & Friday 29th September 2017